Gevo Inc (GEVO) 2.72 $GEVO
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 11:45AM CDT
AEC: 28.45 (+0.04), SMCI: 30.44 (-0.79), CAMP: 20.34 (-1.41), GEVO: 2.72 (-0.10), DSKX: 1.60 (-0.13), CCIH: 14.38 (-0.61), ENZN: 1.72 (+0.18), NRP: 5.26 (-0.57), PARN: 4.25 (-0.05), GBSN: 4.17 (-0.53), AMSC: 6.88 (-3.12), PW: 6.25 (+0.07), EARS: 4.78 (-0.17), EMMS: 1.50 (-0.09), COOL: 1.34 (-0.06), LOOK: 1.97 (+0.37), ONVO: 5.19 (+0.12), HMNY: 2.89 (+0.09), PKT: 11.43 (-0.02), ZHNE: 1.95 (+0.01)
Gevo Announces 1-for-15 Reverse Stock Split
GlobeNewswire - Mon Apr 20, 3:30PM CDT
Gevo, Inc. (Nasdaq:GEVO) announced today that it will effect a 1-for-15 reverse stock split previously approved by the Company's stockholders at a special meeting held on April 13, 2015. The 1-for-15 reverse stock split will be effective as of the close of business on April 20, 2015 and the Company's common stock will begin trading on a split-adjusted basis on Tuesday, April 21, 2015.
GEVO: 2.72 (-0.10)
Insider Trading Alert - MNR, PF And GEVO Traded By Insiders
at The Street - Fri Apr 17, 9:45AM CDT
Stocks with insider trader activity include MNR, PF and GEVO
PF: 40.93 (+0.09), MNR: 10.75 (+0.10), GEVO: 2.72 (-0.10)
Gevo's Reverse Split Opens The Door For One Final Raise
Dallas Salazar - at Seeking Alpha - Wed Apr 15, 7:34AM CDT
GEVO: 2.72 (-0.10)
Insider Trading Alert - GEVO, LDRH And USNA Traded By Insiders
at The Street - Mon Apr 13, 10:00AM CDT
Stocks with insider trader activity include GEVO, LDRH and USNA
LDRH: 36.92 (-0.14), USNA: 128.29 (+0.17), GEVO: 2.72 (-0.10)
Form 4: Update Filing for Gevo Inc (GEVO)
Vickers Stock Research - Sat Apr 11, 3:45AM CDT
Below are the three companies in the Commodity Chemicals industry with the highest EBITDA Growth (next year estimate vs. LTM). EBITDA Growth can be valuable in predicting future cash flow generation and earnings power. Koppers Holdings ranks highest with a EBITDA growth of 135.2%. Following is Georgia Gulf with a EBITDA growth of 75.6%. Arabian American Dev ranks third highest with a EBITDA growth of 60.0%.
GEVO: 2.72 (-0.10)
EPA reaches deal with oil industry to issue overdue biofuel quotas
Seeking Alpha - at Seeking Alpha - Fri Apr 10, 4:17PM CDT
PSX: 81.59 (+0.36), AMRS: 2.52 (-0.09), PBF: 29.65 (+0.82), CDTI: 1.88 (+0.02), CVI: 42.57 (+1.04), WNR: 47.03 (+1.27), HFC: 39.76 (+1.26), GEVO: 2.72 (-0.10), VLO: 60.05 (+0.82), REGI: 9.20 (+0.06), TSO: 89.63 (+3.13), MPC: 103.15 (+1.46), ALJ: 16.83 (+0.33), FF: 11.18 (+0.03), SZYM: 3.79 (-0.11)
Synthetic Biology - Global Strategic Business Report 2015-2020
M2 - Wed Apr 08, 3:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t3bgw8/synthetic_biology) has announced the addition of the "Synthetic Biology - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Synthetic Biology in US$ Thousands by the following Product Segments: Enabled Products, and Others. The report also analyzes the market by the following Application Areas: Energy and Chemicals, Biotechnology and Pharmaceuticals, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 51 companies including many key and niche players such as: Players Focused on Synthetic Biology Applications - Amyris, Inc. (US) - BP PLC. (UK) - Chromatin Inc. (US) - Evolva SA (Switzerland) - Gevo, Inc. (US) - Joule Unlimited, Inc. (US) - Metabolix (US) - MorphoSys AG (Germany) - Sapphire Energy, Inc. (US) - Solazyme, Inc. (US) - Synthetic Biologics, Inc. (US) - Synthetic Genomics, Inc. (US) Players Focused on Gene Synthesis and Tools - 454 Life Sciences (US) - Agilent Technologies Inc. (US) - ATG Biosynthetics GmbH (Germany) - DNA2.0 (US) - Epoch Life Science, Inc. (US) - Gen9, Inc. (US) - GenScript USA, Inc. (US) - Gingko Bioworks, Inc. (US) - Intrexon Corporation (US) - LC Sciences LLC (US) - Life Technologies Corp. (US) - OPXBIO, Inc. (US) - OriGene Technologies, Inc. (US) - Sangamo BioSciences, Inc. (US) - Verdezyne, Inc. (US Key Topics Covered: 1. OUTLOOK 2. INDUSTRY OVERVIEW 3. MARKET TRENDS, DRIVERS, AND ISSUES 4. KEY RESEARCH FINDINGS ON SYNTHETIC BIOLOGY 5. SYNTHETIC BIOLOGY - AN OVERVIEW 6. PRODUCT INNOVATIONS/INTRODUCTIONS 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 51 (including Divisions/Subsidiaries (52) - The United States (41) - Canada (1) - Europe (
- France (1) - Germany (3) - The United Kingdom (1) - Spain (1) - Rest of Europe (2) - Asia-Pacific (Excluding Japan) (2) For more information visit http://www.researchandmarkets.com/research/t3...ic_biology
SYN: 2.33 (+0.01), AMRS: 2.52 (-0.09), A: 42.49 (-0.13), SGMO: 14.70 (-0.84), XON: 44.10 (-0.91), GEVO: 2.72 (-0.10), SZYM: 3.79 (-0.11)
Oil, Gas and Consumable Fuels Equities Update -- Exxon Mobil, BP PLC, Occidental Petroleum, Gevo Inc., and Concho Resources
PR Newswire - Tue Apr 07, 8:15AM CDT
Editor Note: For more information about this release, please scroll to bottom.
CXO: 125.84 (-0.64), XOM: 86.97 (-0.57), BP: 43.46 (-0.14), GEVO: 2.72 (-0.10), OXY: 79.77 (-0.27)
Gevo's 'Starving Time' Is Unlikely To End Well For Its Investors
Tristan R. Brown - at Seeking Alpha - Tue Mar 31, 7:02AM CDT
GEVO: 2.72 (-0.10)
GEVOnomics
Dallas Salazar - at Seeking Alpha - Fri Mar 27, 2:08PM CDT
GEVO: 2.72 (-0.10)
Gevo's (GEVO) CEO Pat Gruber on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Mar 26, 9:39PM CDT
GEVO: 2.72 (-0.10)
Gevo (GEVO) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Mar 26, 3:25PM CDT
GEVO: 2.72 (-0.10)
Gevo beats by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 3:03PM CDT
GEVO: 2.72 (-0.10)
Gevo Reports Fourth Quarter 2014 Financial Results
GlobeNewswire - Thu Mar 26, 3:01PM CDT
Significant Progress Made on Commercial Production of Isobutanol at Luverne, Focus Turns to Licensing
GEVO: 2.72 (-0.10)
Insider Trading Alert - VNR, GEVO And TRC Traded By Insiders
at The Street - Thu Mar 26, 10:15AM CDT
Stocks with insider trader activity include VNR, GEVO and TRC
TRC: 25.42 (+0.55), GEVO: 2.72 (-0.10), VNR: 16.85 (+0.22)
Gevo's Praj Press Release: Productive But Mostly Distracting At This Point
Dallas Salazar - at Seeking Alpha - Wed Mar 25, 6:01AM CDT
GEVO: 2.72 (-0.10)
Gevo Signs Strategic Alliance Memorandum of Understanding With Praj
GlobeNewswire - Tue Mar 24, 8:00AM CDT
Gevo, Inc. (Nasdaq:GEVO), announced today that Praj Industries Limited ("Praj"
has signed a memorandum of understanding (MOU) to become a Gevo licensee for producing renewable isobutanol at sugar-based ethanol plants.
GEVO: 2.72 (-0.10)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 11:45AM CDT
AEC: 28.45 (+0.04), SMCI: 30.44 (-0.79), CAMP: 20.34 (-1.41), GEVO: 2.72 (-0.10), DSKX: 1.60 (-0.13), CCIH: 14.38 (-0.61), ENZN: 1.72 (+0.18), NRP: 5.26 (-0.57), PARN: 4.25 (-0.05), GBSN: 4.17 (-0.53), AMSC: 6.88 (-3.12), PW: 6.25 (+0.07), EARS: 4.78 (-0.17), EMMS: 1.50 (-0.09), COOL: 1.34 (-0.06), LOOK: 1.97 (+0.37), ONVO: 5.19 (+0.12), HMNY: 2.89 (+0.09), PKT: 11.43 (-0.02), ZHNE: 1.95 (+0.01)
Gevo Announces 1-for-15 Reverse Stock Split
GlobeNewswire - Mon Apr 20, 3:30PM CDT
Gevo, Inc. (Nasdaq:GEVO) announced today that it will effect a 1-for-15 reverse stock split previously approved by the Company's stockholders at a special meeting held on April 13, 2015. The 1-for-15 reverse stock split will be effective as of the close of business on April 20, 2015 and the Company's common stock will begin trading on a split-adjusted basis on Tuesday, April 21, 2015.
GEVO: 2.72 (-0.10)
Insider Trading Alert - MNR, PF And GEVO Traded By Insiders
at The Street - Fri Apr 17, 9:45AM CDT
Stocks with insider trader activity include MNR, PF and GEVO
PF: 40.93 (+0.09), MNR: 10.75 (+0.10), GEVO: 2.72 (-0.10)
Gevo's Reverse Split Opens The Door For One Final Raise
Dallas Salazar - at Seeking Alpha - Wed Apr 15, 7:34AM CDT
GEVO: 2.72 (-0.10)
Insider Trading Alert - GEVO, LDRH And USNA Traded By Insiders
at The Street - Mon Apr 13, 10:00AM CDT
Stocks with insider trader activity include GEVO, LDRH and USNA
LDRH: 36.92 (-0.14), USNA: 128.29 (+0.17), GEVO: 2.72 (-0.10)
Form 4: Update Filing for Gevo Inc (GEVO)
Vickers Stock Research - Sat Apr 11, 3:45AM CDT
Below are the three companies in the Commodity Chemicals industry with the highest EBITDA Growth (next year estimate vs. LTM). EBITDA Growth can be valuable in predicting future cash flow generation and earnings power. Koppers Holdings ranks highest with a EBITDA growth of 135.2%. Following is Georgia Gulf with a EBITDA growth of 75.6%. Arabian American Dev ranks third highest with a EBITDA growth of 60.0%.
GEVO: 2.72 (-0.10)
EPA reaches deal with oil industry to issue overdue biofuel quotas
Seeking Alpha - at Seeking Alpha - Fri Apr 10, 4:17PM CDT
PSX: 81.59 (+0.36), AMRS: 2.52 (-0.09), PBF: 29.65 (+0.82), CDTI: 1.88 (+0.02), CVI: 42.57 (+1.04), WNR: 47.03 (+1.27), HFC: 39.76 (+1.26), GEVO: 2.72 (-0.10), VLO: 60.05 (+0.82), REGI: 9.20 (+0.06), TSO: 89.63 (+3.13), MPC: 103.15 (+1.46), ALJ: 16.83 (+0.33), FF: 11.18 (+0.03), SZYM: 3.79 (-0.11)
Synthetic Biology - Global Strategic Business Report 2015-2020
M2 - Wed Apr 08, 3:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t3bgw8/synthetic_biology) has announced the addition of the "Synthetic Biology - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Synthetic Biology in US$ Thousands by the following Product Segments: Enabled Products, and Others. The report also analyzes the market by the following Application Areas: Energy and Chemicals, Biotechnology and Pharmaceuticals, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 51 companies including many key and niche players such as: Players Focused on Synthetic Biology Applications - Amyris, Inc. (US) - BP PLC. (UK) - Chromatin Inc. (US) - Evolva SA (Switzerland) - Gevo, Inc. (US) - Joule Unlimited, Inc. (US) - Metabolix (US) - MorphoSys AG (Germany) - Sapphire Energy, Inc. (US) - Solazyme, Inc. (US) - Synthetic Biologics, Inc. (US) - Synthetic Genomics, Inc. (US) Players Focused on Gene Synthesis and Tools - 454 Life Sciences (US) - Agilent Technologies Inc. (US) - ATG Biosynthetics GmbH (Germany) - DNA2.0 (US) - Epoch Life Science, Inc. (US) - Gen9, Inc. (US) - GenScript USA, Inc. (US) - Gingko Bioworks, Inc. (US) - Intrexon Corporation (US) - LC Sciences LLC (US) - Life Technologies Corp. (US) - OPXBIO, Inc. (US) - OriGene Technologies, Inc. (US) - Sangamo BioSciences, Inc. (US) - Verdezyne, Inc. (US Key Topics Covered: 1. OUTLOOK 2. INDUSTRY OVERVIEW 3. MARKET TRENDS, DRIVERS, AND ISSUES 4. KEY RESEARCH FINDINGS ON SYNTHETIC BIOLOGY 5. SYNTHETIC BIOLOGY - AN OVERVIEW 6. PRODUCT INNOVATIONS/INTRODUCTIONS 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 51 (including Divisions/Subsidiaries (52) - The United States (41) - Canada (1) - Europe (
- France (1) - Germany (3) - The United Kingdom (1) - Spain (1) - Rest of Europe (2) - Asia-Pacific (Excluding Japan) (2) For more information visit http://www.researchandmarkets.com/research/t3...ic_biology SYN: 2.33 (+0.01), AMRS: 2.52 (-0.09), A: 42.49 (-0.13), SGMO: 14.70 (-0.84), XON: 44.10 (-0.91), GEVO: 2.72 (-0.10), SZYM: 3.79 (-0.11)
Oil, Gas and Consumable Fuels Equities Update -- Exxon Mobil, BP PLC, Occidental Petroleum, Gevo Inc., and Concho Resources
PR Newswire - Tue Apr 07, 8:15AM CDT
Editor Note: For more information about this release, please scroll to bottom.
CXO: 125.84 (-0.64), XOM: 86.97 (-0.57), BP: 43.46 (-0.14), GEVO: 2.72 (-0.10), OXY: 79.77 (-0.27)
Gevo's 'Starving Time' Is Unlikely To End Well For Its Investors
Tristan R. Brown - at Seeking Alpha - Tue Mar 31, 7:02AM CDT
GEVO: 2.72 (-0.10)
GEVOnomics
Dallas Salazar - at Seeking Alpha - Fri Mar 27, 2:08PM CDT
GEVO: 2.72 (-0.10)
Gevo's (GEVO) CEO Pat Gruber on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Mar 26, 9:39PM CDT
GEVO: 2.72 (-0.10)
Gevo (GEVO) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Mar 26, 3:25PM CDT
GEVO: 2.72 (-0.10)
Gevo beats by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 3:03PM CDT
GEVO: 2.72 (-0.10)
Gevo Reports Fourth Quarter 2014 Financial Results
GlobeNewswire - Thu Mar 26, 3:01PM CDT
Significant Progress Made on Commercial Production of Isobutanol at Luverne, Focus Turns to Licensing
GEVO: 2.72 (-0.10)
Insider Trading Alert - VNR, GEVO And TRC Traded By Insiders
at The Street - Thu Mar 26, 10:15AM CDT
Stocks with insider trader activity include VNR, GEVO and TRC
TRC: 25.42 (+0.55), GEVO: 2.72 (-0.10), VNR: 16.85 (+0.22)
Gevo's Praj Press Release: Productive But Mostly Distracting At This Point
Dallas Salazar - at Seeking Alpha - Wed Mar 25, 6:01AM CDT
GEVO: 2.72 (-0.10)
Gevo Signs Strategic Alliance Memorandum of Understanding With Praj
GlobeNewswire - Tue Mar 24, 8:00AM CDT
Gevo, Inc. (Nasdaq:GEVO), announced today that Praj Industries Limited ("Praj"
has signed a memorandum of understanding (MOU) to become a Gevo licensee for producing renewable isobutanol at sugar-based ethanol plants. GEVO: 2.72 (-0.10)
